Advanced in Von Willebrand Disease (VWD)

Dr. Eric S. Mullins

Pediatric Hematology Oncology
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Von Willebrand Disease (VWD)
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Mullins is a Pediatric Hematologist Oncology provider in Cincinnati, Ohio. Dr. Mullins is rated as an Advanced provider by MediFind in the treatment of Von Willebrand Disease (VWD). His top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Von Willebrand Disease (VWD).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

CHILDREN'S HOSPITAL MEDICAL CENTER
3333 Burnet Ave, Cincinnati, OH 45229

Additional Areas of Focus

Dr. Mullins has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Recruiting
Publish Date: April 22, 2025
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: BAX-888 Adeno-Associated Virus Serotype 8 Vector B-Domain Deleted Factor VIII Vaccine
Study Phase: Phase 1/Phase 2
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
View 4 Less Clinical Trials

38 Total Publications

Hematologists' comfort and experiences with providing care to transgender youth.
Hematologists' comfort and experiences with providing care to transgender youth.
Journal: Blood vessels, thrombosis & hemostasis
Published: October 22, 2024
Similar Doctors
Experienced in Von Willebrand Disease (VWD)
Dr. Cristina Tarango
Pediatric Hematology Oncology
Experienced in Von Willebrand Disease (VWD)
Dr. Cristina Tarango
Pediatric Hematology Oncology
3333 Burnet Ave., Ml 7015, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Cristina Tarango is a Pediatric Hematologist Oncology provider in Cincinnati, Ohio. Dr. Tarango is rated as a Distinguished provider by MediFind in the treatment of Von Willebrand Disease (VWD). Her top areas of expertise are Hemophilia A, Hemophilia B, Mesenteric Venous Thrombosis, Thrombectomy, and Angioplasty.

Experienced in Von Willebrand Disease (VWD)
Dr. Lori A. Luchtman
Pediatric Hematology Oncology
Experienced in Von Willebrand Disease (VWD)
Dr. Lori A. Luchtman
Pediatric Hematology Oncology

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4200
Languages Spoken:
English
See accepted insurances

Lori Luchtman is a Pediatric Hematologist Oncology provider in Cincinnati, Ohio. Dr. Luchtman is rated as an Experienced provider by MediFind in the treatment of Von Willebrand Disease (VWD). Her top areas of expertise are Evans Syndrome, Hemoglobin C Disease, Hemoglobinopathy, and Hemoglobin E Disease.

Experienced in Von Willebrand Disease (VWD)
Dr. Maria E. Carter
Pediatric Hematology Oncology
Experienced in Von Willebrand Disease (VWD)
Dr. Maria E. Carter
Pediatric Hematology Oncology
3333 Burnet Ave Ml 7015, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Maria Carter is a Pediatric Hematologist Oncology provider in Cincinnati, Ohio. Dr. Carter is rated as an Advanced provider by MediFind in the treatment of Von Willebrand Disease (VWD). Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Hereditary Spherocytosis, Sickle Cell Disease, and Febrile Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mullins's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile